Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2026)

Amylyx Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 10.96% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 10.96% YoY), while the FY2025 annual figure was $22.7 million, down 20.13% from the prior year.
• Total Current Liabilities was $16.0 million for Q1 2026 at Amylyx Pharmaceuticals, down from $22.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $91.6 million in Q1 2024 to a low of $16.0 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $42.7 million across 5 years, with a median of $32.6 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 167.93% in 2022, then plunged 80.43% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $46.6 million in 2022, then surged by 76.02% to $82.0 million in 2023, then sank by 65.38% to $28.4 million in 2024, then declined by 20.13% to $22.7 million in 2025, then slipped by 29.63% to $16.0 million in 2026.
• The last three Total Current Liabilities figures came in at $16.0 million (Q1 2026), $22.7 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.